India  

Serum Institute of India

Indian biotechnological company, vaccine manufacturer

Serum Institute of India    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Serum Institute of India: Indian biotechnological company, vaccine manufacturer
Serum Institute of India is a manufacturer of immunobiological drugs including vaccines in India. It was founded by Cyrus Poonawalla in 1966. The company is a subsidiary of the holding company Poonawalla Investment and Industries.

0
shares
ShareTweetSavePostSend
 

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon [Video]

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon

Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being..

Credit: HT Digital Content     Duration: 01:19Published
Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning [Video]

Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning

From the CEO of the world's largest vaccine manufacturer commenting on the possible timeline of the final vaccine reaching every person on the planet, to the World Health Organisation warning that the..

Credit: HT Digital Content     Duration: 02:18Published
Covid: Serum Institute begins human trials, 5 volunteers given first shot [Video]

Covid: Serum Institute begins human trials, 5 volunteers given first shot

The Phase II human clinical trial of the Oxford COVID-19 vaccine candidate, being manufactured by the city-based Serum Institute of India (SII), began at a medical college and hospital here on..

Credit: HT Digital Content     Duration: 02:01Published
Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR [Video]

Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR

At present country has three Indian COVID-19 vaccines which are in different phases of clinical testing, said Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava on Tuesday...

Credit: HT Digital Content     Duration: 06:42Published
COVID-19: Oxford vaccine's late stage trials to start in a week in India, says ICMR [Video]

COVID-19: Oxford vaccine's late stage trials to start in a week in India, says ICMR

Director General of Indian Council of Medical Research, Dr Balram Bhargava on August 04 stated that Oxford vaccine, being manufactured by Serum Institute of India, got approval for phase 2 and 3..

Credit: ANI     Duration: 02:24Published
COVID update: India to start late stage trials of Oxford vaccine, Shivraj tests positive again [Video]

COVID update: India to start late stage trials of Oxford vaccine, Shivraj tests positive again

The Drugs Controller General of India (DCGI) has given approval to Serum Institute of India (SII), Pune, to conduct Phase II and III clinical trials of Oxford University. According to the World Health..

Credit: ANI     Duration: 01:38Published

You Might Like


Serum to make extra 100 million vaccine doses

Serum Institute of India will produce up to an additional 100 million COVID-19 vaccine doses for India and low and middle-income countries in 2021.The company made this announcement taking forward the..
IndiaTimes - Published

I wish government's Covid vaccine strategy was 'Mann ki Baat': Rahul Gandhi

Gandhi's tweet came after Prime Minister Narendra Modi aired his monthly 'Mann ki baat' programme on the All India Radio (AIR). Along with his comment, Gandhi shared a news report regarding Serum..
IndiaTimes - Published

Serum Institute CEO lauds PM Narendra Modi's COVID-19 vaccine vision day after challenging Centre on pandemic response

It is to be noted that the Serum Institute of India is all set to begin phase three trials of the Covishield Vaccine developed by AstraZeneca and Oxford University at Sassoon General Hospital in Pune.
DNA - Published

Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla asks

On September 16, the Drugs Controller General of India (DCGI) allowed the Serum Institute of India (SII) to restart its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
DNA - Published

Phase 3 human clinical trial of Oxford vaccine begins in Pune

The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at the state-run Sassoon General Hospital..
IndiaTimes - Published

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
DNA - Published

DCGI orders Serum Institute of India to suspend recruitment for Oxford Covid-19 vaccine trials


IndiaTimes - Published

India will have 'approved' Covid vaccine by 2021 Q1: Report

India is on course to have an "approved" vaccine within the first quarter of calendar year 2021 and Pune- based Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is..
IndiaTimes - Published

Oxford Covid vaccine trail: Vital signs of volunteers normal, says doctor

Two men, aged 32 and 48, were given the first shot of the 'Covishield' vaccine, being manufactured by Pune-based Serum Institute of India (SII), at Bharti Vidyapeeth's Medical College and Hospital on..
IndiaTimes - Published

Covid-19 vaccine: Govt panel meets representatives of leading domestic manufacturers

The national expert group on vaccine administration for Covid-19 met representatives of leading domestic manufactures, including Serum Institute of India, Bharat Biotech and Zydus Cadila, on Monday to..
IndiaTimes - Published

Serum Institute of India enters into partnership to accelerate manufacture, delivery of Covid vaccines for India

The Serum Institute of India (SII) has entered into a new landmark partnership with Gavi, the Vaccine Alliance and the Bill and Melinda Gates Foundation, to accelerate the manufacture and delivery of..
IndiaTimes - Published

DCGI nod to Serum Institute of India for phase 2 & 3 clinical trials of Oxford Covid-19 vaccine

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India for conducting phase 2 and 3 human clinical trials of the Oxford University's Covid-19 vaccine candidate in..
IndiaTimes - Published

Coronavirus vaccine: DCGI gives nod to Serum-Oxford for phase 2, 3 clinical trials in India

DCGI has allowed the Serum Institute of India to conduct phase 2 and 3 human clinical trials in India on the potential COVID19 vaccine.
DNA - Published

Panel recommends permission to Serum Institute for phase 2, 3 human clinical trials of Oxford vaccine candidate

A subject expert committee on Covid-19 on Friday recommended to the country's drug regulator that permission be granted to Serum Institute of India (SII) for conducting the second and third phases of..
IndiaTimes - Published

Seven Indian pharma players race to develop Covid-19 vaccine

At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check the spread of the deadly virus that has already..
IndiaTimes - Published

No proof MMR vaccination offers protection against Covid-19, says Serum Institute


IndiaTimes - Published

How one Indian company could be world's door to a COVID-19 vaccine

If the world is to gain access to a vaccine for COVID-19, there's a good chance it will pass through the doors of Serum Institute of India.
Reuters India - Published

Covid-19: Pune co plans to start vaccine production next month

Pune-based Serum Institute, credited with affordable and innovative therapies like pneumonia and dengue monoclonal vaccines, plans to price the proposed Covid vaccine at around Rs 1,000 per dose in..
IndiaTimes - Published